Press release
(November 2, 2023) - Centralized hub for advanced testing of nucleic acids to simplify mRNA drug substance testing, accelerating critical therapeutic development
SAN DIEGO (November 2, 2023) –TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its Analytical Sciences Center of Excellence (ASCE) hub. Expanding its comprehensive suite of analytical t...(November 1, 2023) - SAN DIEGO –TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and a recognized leader in the production of high-quality nucleic acid-based products, today renews a multi-year supply agreement with Intellia Therapeutics, a pioneering genome editing company.
This agreement ensures the consistent provis...
(May 24, 2023) - GMP Facility Expected to Simplify the mRNA Drug Substance Development Process; Slated to Welcome Customers in Early 2024
SAN DIEGO (May 24, 2023) –TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the expansion of its mRNA m...(May 9, 2023) - Newest cap analog product improves mRNA potency with greater protein expression, offers time and cost savings, and streamlines manufacturing to drive critical therapeutic and vaccine development
SAN DIEGO (May 9, 2023) – TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (NASDAQ:...(September 13, 2022) - TriLink now offers GMP-grade N1-Methyl-Pseudouridine-5’-Triphosphate, a critical raw material for mRNA manufacturing, allowing researchers to accelerate their drug discovery and development timelines and US-source their supply chain.
SAN DIEGO - TriLink BioTechnologies (“TriLink”), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has expanded its GMP-grade product offering to include N1-Methyl-Pseudouridine-5’-Triphosphate (N1meΨTP), a modified nucleoside-triphosph...(July 6, 2022) - Appoints Dr. Kate Broderick as Senior Vice President of Research and Development.
SAN DIEGO, — July 6, 2022 — TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (Maravai) (NASDAQ: MRVI) and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, today announced that Kate Broderick, Ph.D., has joined the Company as Senior Vice President of Research and Development. In this newly created role, Kate will have responsibility for leading TriLink’s research and development strategy and scientific direction. S...(May 24, 2022) - DOD to fund planned manufacturing expansion and to prepare the U.S. for a rapid response to the next pandemic as part of Industrial Base Expansion
SAN DIEGO, — May 24, 2022 — TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (Maravai) (NASDAQ: MRVI), and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, today announced a Cooperative Agreement with the Army Contracting Command, in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-C...(October 4, 2021) - EyeGene expected to utilize TriLink’s CleanCap® technology and modified UTP manufactured by TriLink in the production of its EG-COVID mRNA COVID-19 vaccine for clinical trials
SAN DIEGO, October 4, 2021 — TriLink BioTechnologies (“TriLink”), a Maravai LifeSciences company (Nasdaq: MRVI) and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced today that it expects to supply its proprietary CleanCap® ...(August 3, 2021) - TriLink enables Chula VRC to take its Covid-19 vaccine into a First in Human (FIH) phase 1 clinical trial in Thailand with mRNA manufacturing process development and its proprietary mRNA capping technology, ushering a much-needed vaccine into economically developing countries.
SAN DIEGO — TriLink BioTechnologies (“TriLink”), a Maravai LifeSciences company (Nasdaq: MRVI) and a leader in the production of nucleic acids for research, diagnostics and therapeutics ap... (March 15, 2021) - New integrated offering will help to meet expected increases in global demand by simplifying and accelerating production of GMP-grade mRNA product for downstream vaccine and therapeutic manufacturing.
(August 25, 2020) - Second manufacturing expansion within a year will help meet global demand for research, clinical and GMP grade raw materials as well as research and clinical grade APIs to include mRNA, self-amplifying RNA and plasmid DNA
SAN DIEGO, Calif. — Maravai LifeSciences, a global provider of life science reagents and services to researchers and biotech innovators, is expanding its contract development and manufacturing organization (CDMO) capabilities at TriL...(April 27, 2020) - SAN DIEGO –TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, and Imperial College London, a public research university located in the United Kingdom, announced today that they have entered into a partnership in which TriLink will manufacture self-amplifying RNA (saRNA) for COVID-19 vaccine development. The vaccine development program is led by Professor Robin Shattock, Head of Mucosal Infection and Immunity within the Department of Infectious Disease at ...
(February 11, 2020) - SAN DIEGO – TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced today the addition of two key executives to its leadership team.
Ray Kaczmarek joins TriLink as senior vice president of GMP operations. Kaczmarek, who has over 20 years of experience in pharmaceutical and biotechnology manufacturing and supply chain operations, most recently served as president of Nitto Avecia Pharma Services, a contract development and manufacturing organization support...(January 7, 2020) - Advancements Expected to Accelerate Development of mRNA Therapeutics
SAN DIEGO – TriLink BioTechnologies, a Maravai LifeSciences company and a leader in the production of nucleic acids such as DNA and RNA, announced today that the United States Patent and Trademark Office has issued two new patents to the company. Both patents cover advancements in TriLink’s CleanCap® technology for the co-transcriptional capping of messenger RNAs (mRNAs). Capping is an important step in the production of synthetic mRNA, which is used to develop nucleic acid therapeutics tha...(November 20, 2019) - SAN DIEGO – mRNA Day is being celebrated in the City of San Diego following a proclamation in honor of Maravai LifeSciences and the grand opening of its new headquarters in the City. A leader in providing reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide; Maravai invested $40 million into the 105,000 square-foot headquarters located in Sorrento Valley, which features a 50,000 square foot manufacturing facility with five state-of-the-art cleanrooms for TriLink BioTechnologies, a leader in the synthesis of highly modified nucleic acids includi...
(October 14, 2019) - Two New Sets of Barcode Convert Primers are Optimized for Ion Torrent* Sequencers
SAN DIEGO – TriLink BioTechnologies, a Maravai LifeSciences company and leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, introduces two new primer sets for its CleanTag® kit. The new Ion Torrent Convert barcode primer sets enable small RNA library preparation on the sequencer platform from Thermo Fisher Scientific. TriLink’s CleanTag Small RNA Library Prep Kit has been in use for several years with Illumina* sequencer...(November 29, 2018) - TriLink BioTechnologies, a Maravai LifeSciences company and a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, announced today that the company’s CleanTag® Small RNA Library Prep Kit was the enabling technology in a new study of next-generation sequencing of small RNAs from single cells. The study, Efficient Production of On-Target Reads for Small RNA Sequencing of Single Cells Using Modified Adapters, demonstrates the successful sequencing of small RNA at the single-cell level, a process that had previously proven challenging. The pape...
(October 9, 2018) - Maravai LifeSciences, a leader in providing reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide, today announced that it has hired Christopher Shaffer as senior director of oligonucleotide process development for TriLink BioTechnologies. In this new position, Shaffer will develop and refine processes that improve overall efficiency and will be instrumental when TriLink relocates to a new facility next year. Shaffer will oversee workflows, automation and other elements of testing and manufacturing including scaleup. He will also provide technical support to TriL...
(September 10, 2018) - Maravai LifeSciences, a leader in providing reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide, today announced plans to relocate and expand its TriLink BioTechnologies operations with the signing of a lease on a new facility in the Sorrento Valley area of San Diego. TriLink will consolidate its San Diego facilities into a new 95,000-square-foot space with an option to expand for future growth. The new facility will house the company’s current local staff of more than 150 and can accommodate growth to more than 350 R&D, commercial and manufacturing emplo...
(November 27, 2017) - TriLink BioTechnologies, a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, announced today that Michael Houston, Ph.D., has joined the company as chief scientific officer. In this role he is responsible for the company’s R&D as well as scientific thought leadership.
Houston holds a Ph.D. in bioorganic chemistry and has worked for a range of biotechnology and pharmaceutical companies, including PhaseRx, Marina Biotech, Ascent Therapeutics and Nastech Pharmaceutical. He specializes in oligonucleotide synthesis and therapeutic development....(October 16, 2017) - TriLink BioTechnologies, a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, announced today that Brian Neel has joined the company as chief operating officer. In that role, Neel will be responsible for TriLink BioTechnologies operations including site leadership, facilities, sourcing and manufacturing.
Neel brings more than 15 years of experience in the life science and diagnostic industries to TriLink BioTechnologies. He has worked at Synthetic Genomics, GenMark Diagnostics and Life Technologies (now Thermo Fisher Scientific). With a degree i...(January 10, 2017) - TriLink BioTechnologies, a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, introduces CleanCap – a patented mRNA capping method that overcomes many drawbacks of existing technology. CleanCap, which is available built into TriLink BioTechnologies products or in bulk for customer use, exhibits superior capping efficiencies for higher yield, along with time and cost savings.
"Capping is a critical process in creating viable mRNA constructs that remain biologically active and avoid self/non-self intracellular responses,” explains Anton McCaff...(October 20, 2016) - Maravai LifeSciences, a transformative company in the life science research market, announced today that it has acquired TriLink BioTechnologies, leaders in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics. The acquisition fits with Maravai LifeSciences’ goal of creating a market-leading life science business by bringing investment, strong and experienced leadership, processes and best practices to companies with notable growth potential.
"We are investing in companies like TriLink BioTechnologies that have high-quality products, a history of success a...(March 15, 2015) - TriLink BioTechnologies, a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, introduces CleanTag® – a new technology that addresses one of the biggest problems in NGS library preparation – adapter dimer formation. CleanTag’s modified adapters block adapter-adapter formation, which leads to significantly higher quality sequencing data and increases mappable sequencing reads over existing technology. Even with samples containing low-abundance miRNA, such as blood or plasma, CleanTag delivers superior results.
The CleanTag method...In the News
The Shadow of COVID-19
(The Medicine Maker: November 27, 2023) -
The effects of the biggest healthcare crisis in modern memory continues to linger, but lessons have been learned. In Europe, the European Commission has already struck deals to ensure manufacturing capacity for future emergencies.The WHO declared the COVID-19 pandemic officially over in May 2023, but the disease continues to make media headlines. In the UK, for exa...
Medicine’s Hot New Modality, mRNA, Faces Unclear Regulatory Landscape
(BioSpace: October 25, 2023) - While medicines consisting of modified RNA have been decades in the making, it took the pressure of a global pandemic to push the promising technology past hurdles and onto the market. Thanks to a great deal of innovation, mRNA is now a household name and a rapidly expanding industry for the biopharma world beyond COVID-19. Over 250 ...
The Bright Future of mRNA Vaccines
(ID Transmission: October 9, 2023) - Although mRNA technology has been researched for decades, the COVID-19 pandemic provided an excellent example of the incredible potential of mRNA – especially when it comes to combating infectious diseases. The speed and efficiency of the production process is where mRNA vaccines really stand out from traditional vaccines, but they also offer greater precision regarding what cells are producing and how that alte...
Realizing the Promise of mRNA Tech to Revolutionize Global Health
(Today's Clinical Lab: October 3, 2023) - In today’s post-pandemic world, the potential impact of messenger RNA (mRNA) technology extends far beyond vaccines, signaling a paradigm shift in global health. With this versatile tool, public health experts and biopharmaceutical leaders stand poised to gain significant ground in the fight against emerging health threats and conditions.
An Interview with Jason Downing, Sr Product Manager, Trilink BioTechnologies
(American Pharmaceutical Review: October 1, 2023) - Although it is a ubiquitous biological molecule, mRNA is notoriously unstable. As we continue to innovate and explore the possibilities of using mRNA in next-generation vaccines and therapeutics, a key consideration requires addressing the stability issue. Adding a cap to mRNA is analogous to having a bumper on a car. While mRNA caps have many other uses, one of their primary functions is acting as a protective ba...
Pharma Manufacturing announces the 2023 Pharma Innovation Award winners
(pharma Manufacturing: September 26, 2023) - Pharma Manufacturing, an Endeavor Business Media brand, is proud to unveil this year's Pharma Innovation Award winners. The Pharma Innovation Awards are an annual celebration of new technologies and services that help advance product quality, risk reduction, and manufacturing efficiency.
Optimizing mRNA therapeutics
(pharma Manufacturing: August 31, 2023) - The approval and widespread use of messenger RNA (mRNA)-based vaccines for SARS-CoV-2 represented a significant milestone in the use of mRNA as a therapeutic agent. These products reified the incredible potential of in vitro transcribed (IVT) mRNA theoretically capable of producing nearly any functional protein or peptide in the body. mRNA-based therapeutics were first conceptualized more than three decades ago wi...
The Top 25 Companies of San Diego for 2023
(The Business Report: August 28, 2023) - The Business Report is pleased to announce The Top 25 Companies of San Diego for 2023. Characterized by pioneering technology firms, leading research institutions, the world's highest concentration of military assets, and a thriving tourism sector, the San Diego area boasts one of the most vibrant economies nationwide. Known as "America's Finest City," there are a multitude of reasons for San Diego's appeal to bus...
Manufacturing key to overcoming the next pandemic
(Pharmaforum: August 23, 2023) - Ben Hargreaves looks at the way governments are preparing for a future pandemic. One of the key lessons from COVID-19 was ensuring that sufficient manufacturing capacity is readily available, and this is the area where investment and action are taking place.
At Least 6 Companies Working on COVID Vaccines in San Diego
(10 News San Diego: June 24, 2020) - At least six companies are working on COVID-19 vaccine candidates in San Diego, all within a 1.5-mile radius of where the I-5 and I-805 split. Locally, the farthest along appears to be Inovio Pharmaceuticals, which plans to launch a Phase 2 trial next month, potentially with a simultaneous Phase 3 trial. A Phase 3 trial is the final step in vaccine testing, with thousands of participants. The company is developing...
Coronavirus: Human Trial of New Vaccine Begins in UK
(BBC News: June 24, 2020) - Volunteers have begun being immunised with a new UK coronavirus vaccine. About 300 people will have the vaccine over the coming weeks, as part of a trial led by Prof Robin Shattock and his colleagues, at Imperial College London. Tests in animals suggest the vaccine is safe and triggers an effective immune response. Experts at Oxford University have already started human trials. The trials are among many across the...
mRNA Day: TriLink, Maravai Look to RNA, Oligonucleotides, and San Diego for Growth
(Genetic Engineering & Biotechnology News: December 20, 2019) - A San Diego manufacturer of highly-modified nucleic acids and its parent company have concluded that development of RNA- and oligonucleotide-based therapeutics—as well as the region’s biopharma cluster—will both grow strongly enough in the near future to justify the companies’ recent $50-million investment in relocation and expansion within the city...
RNA Epitranscriptome: Role of the 5’ Cap
(Genetic Engineering & Biotechnology News: May 1, 2019) - Epigenetic modification of RNA, the RNA analog of the DNA epigenome, has been observed for over 40 years and is known as the epitranscriptome. Messenger RNAs (mRNAs) in particular are post-transcriptionally modified, obtaining base modifications as well as 2ʹ methylation of sugars near the 5ʹ cap. Cap modifications identify the mRNA as self rather than foreign, and modulate stability, translation, decappin...
Address Manufacturing and Look Beyond Cancer, Panel Advises Cell and Gene Therapy Companies
(Genetic Engineering & Biotechnology News: March 22, 2019) - The ability of cell and gene therapy companies to raise capital this year will hinge on their ability to address the manufacturing of their products as well as address medical needs beyond cancer, a panel of three investors and an industry executive agreed yesterday...
Contact
CG Life
Email: [email protected]
Phone: 847-702-8099